

INDEPENDENT AUDITORS' REPORT

TO THE MEMBERS OF LIVA NUTRITIONS LIMITED

REPORT ON THE AUDIT OF THE FINANCIAL STATEMENTS

Opinion

We have audited the accompanying financial statements of **LIVA NUTRITIONS LIMITED** ('the Company'), which comprise the Balance Sheet as at March 31, 2026, the Statement of Profit and Loss (including other comprehensive income), the Statement of cash flows and the Statement of changes in Equity for the year then ended, and notes to the financial statements, including a summary of material accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ('the Act') in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ('Ind AS') and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2026, and its loss, total comprehensive income, cash flows and the changes in equity for the year ended on that date.

Basis for Opinion

We conducted our audit of the financial statements in accordance with the Standards on Auditing ('SAs') specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the financial statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('ICAI') together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the financial statements.

Information other than the Financial Statements and Auditor's Report thereon

- The Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Management Discussion and Analysis, Business Responsibility and Sustainability Report, Corporate Governance Report and Directors' Report, but does not include the financial statements and our audit reports thereon.
- Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.
- In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.
- If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the financial statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, cash flows and changes in equity of the Company in

accordance with the Ind AS and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate implementation and maintenance of accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibility for the Audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- a) Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- b) Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- c) Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- d) Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- e) Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

As required by Section 143(3) of the Act, we report that:

- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- b) In our opinion, proper books of account as required by law have been kept, so far as it appears from our examination of those books.
- c) The Balance Sheet, the Statement of Profit and Loss (including Other Comprehensive Income), the Cash Flow Statement and Statement of Changes in Equity dealt with by this report are in agreement with the books of account.
- d) In our opinion, the aforesaid financial statements comply with the Ind AS specified under Section 133 of the Act read with Rule 7 of the Companies (Accounts) Rules, 2014.
- e) On the basis of the written representations received from the directors as on March 31, 2026 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2026 from being appointed as a director in terms of section 164(2) of the Act.
- f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B". Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls over financial reporting.
- g) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended, in our opinion and to the best of our information and according to the explanations given to us, no remuneration has been paid by the Company to its directors during the year.

- h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- i. The Company does not have any pending litigations which would impact its financial position.
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - iii. There were no amounts required to be transferred to the Investor Education and Protection Fund by the Company.
 - iv. (a) The management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other persons or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
 - (b) The management has represented that, to the best of its knowledge and belief, no funds have been received by the company from any persons or entities, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
 - (c) Based on such audit procedures that we have considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations given under (a) and (b) above, contain any material misstatement.
 - v. No dividend is declared or paid during the year by the company, so reporting under clause 11(f) of Rule 11 of the Companies (Audit and Auditors) Rules, 2014, is not applicable.
 - vi. Based on our examination, which included test checks, the Company has used accounting software for maintaining its books of account for the financial year ended 31st March, 2026 which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software. Further, during the course of our audit, we did not come across any instances of the audit trail feature being tempered with. The audit trail has been preserved by the company as per the statutory requirements for record retention.

For **MUKESH M. SHAH & CO.,**
Chartered Accountants
Firm Registration No.: 106625W

SD/-

Place: Ahmedabad
Date: 29th April, 2026
UDIN: 26102651ZANIKT5880

Suvrat S. Shah
Partner
Membership No.: 102651

“Annexure A” to the Independent Auditors’ Report

The Annexure referred to in Independent Auditors’ Report to the members of the Company on the financial statements for the year ended March 31, 2026

Based on the audit procedures performed for the purpose of reporting a true and fair view on the financial statements of the Company and taking into consideration the information and explanations given to us and the books of account and other records examined by us in the normal course of audit, we report that:

1. The company does not hold any Property, Plant and Equipment or Intangible Assets, hence clause (i) (a), (i)(b), (i)(c), (i)(d) and (i) (e) of Paragraph 3 of the Order are not applicable to the company for the year under review.
2. The company does not deal in inventory hence this clause is not applicable to the company for the year under review.
3. According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not made any investments in, provided any guarantee or security, and granted any loans or advances in the nature of loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or any other parties during the year, and hence reporting under clause (iii) of the Order is not applicable.
4. According to the information and explanations given to us and on the basis of our examination of the records, the Company has not given any loans, or provided any guarantee or security or made any investments to which provisions of Section 185 and Section 186 of the Companies Act, 2013 are applicable, and accordingly paragraph 3(iv) of the Order is not applicable to the company.
5. The Company has not accepted any deposits within the meaning of the provisions of section 73 to 76 of the Act or any other relevant provisions of the Act and the rules framed thereunder. Further, according to the information and explanations given to us, no order has been passed by the Company Law Board or National Company Law Tribunal or Reserve Bank of India or any court or any other Tribunal, in this regard.
6. In absence of any manufacturing activity carried out by the company, the requirement of maintenance of cost records under sub section 1 of section 148 of the Companies Act ,2013 are not applicable to the company.
7. (a) According to the information and explanations given to us and on the basis of our examination of the records, the company has been regular in depositing undisputed statutory dues including Goods and Services tax, Provident Fund, Employees’ State Insurance, Income tax, Sales tax, Service tax, Duty of Custom, Duty of Excise, Value added Tax, Cess and any other material statutory dues wherever payable have been paid during the year with the appropriate authorities. Moreover, as at 31st March 2026, there are no such undisputed dues payable for a period of more the six months from the day they became payable.

(b) According to the information and explanations given to us, there is no due under dispute for the Income Tax, Sales Tax, Value added Tax, Excise Duty and Service Tax, GST and other material statutory dues as at 31st March, 2026.
8. According to the information and explanations given to us, there were no transactions relating to previously unrecorded income that were surrendered or disclosed as income in the tax assessments under the Income Tax Act, 1961 (43 of 1961) during the year.
9. (a) According to the information and explanations given to us and on the basis of our examination of the books of account, the Company has not defaulted in repayment of loans or other borrowings or in the payment of interest to any lender during the year.

- (b) According to the information and explanations given to us and on the basis of our audit procedure, we report that the Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.
 - (c) According to the information and explanations given to us, the Company has not availed term loans, hence reporting under Paragraph 3(ix)(c) is not applicable.
 - (d) According to the information and explanations given to us, and the procedures performed by us, and on overall examination of financial statements of the Company, we report that funds raised on short term basis have, not been used during the year for the long-term purpose by the Company.
 - (e) According to the information and explanations given to us, and the procedures performed by us, and on overall examination of financial statements of the Company, we report that the company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries.
 - (f) According to the information and explanations given to us, and the procedures performed by us, we report that the Company has not raised any loans during the year on the pledge of securities held in its subsidiary companies.
10. (a) The Company did not raise any money by way of initial public offer or further public offer (including debt instruments) during the year and hence reporting under this clause of the Order is not applicable to the Company.
 - (b) During the year, the Company has not made any preferential allotment or private placement of shares or convertible debentures (fully, partially or optionally convertible) and hence reporting under this clause of the Order is not applicable to the Company;
 11. (a) To the best of our knowledge and according to the information and explanations given to us, no fraud by the Company or on the Company has been noticed or reported during the year.
 - (b) According to the information and explanations given to us, no report under sub-section (12) of section 143 of the Companies Act has been filed by the auditors in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government.
 - (c) According to the information and explanations given by management/Audit Committee, there were no whistle blower complaints received by the Company during the year.
 12. The Company is not a Nidhi Company and hence reporting under this clause of the Order is not applicable.
 13. According to the information and explanations given to us and based on our examination of the records of the Company, there are no related party transactions entered into by the company during the current year, hence, the reporting requirement under clause (xiii) of the order is not applicable.
 14. According to the information and explanations given to us and based on our examination of the records of the Company, the company is not required to undergo internal audit and hence the clause is not applicable to the company.
 15. According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not entered into any non-cash transactions with any of its directors or persons connected with such directors and hence provisions of section 192 of the Companies Act, 2013 are not applicable to the Company.
 16. According to the information and explanations given to us and based on our examination of the records of the Company, we report that

- (a) The Company is not required to be registered under section 45-IA of the Reserve Bank of India Act 1934;
 - (b) The company has not conducted any non-banking or housing finance activities during the year;
 - (c) The Company is not a Core Investment Company, as defined in the regulations made by the Reserve Bank of India;
 - (d) The Group has more than One Core Investment Company (two Core Investment Companies) as part of the Group.
17. The Company has incurred cash losses Rs. 33 thousand in the current financial year, and Rs. 23 thousand in the immediately preceding financial year.
18. There has been no resignation of the statutory auditors of the Company during the year. Accordingly, reporting under clause 3(xviii) of the Order is not applicable.
19. On the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements and our knowledge of the Board of Directors and Management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.
20. On the basis of information and explanations given to us and based on the examination of the records of the company, the provisions of Corporate Social Responsibility ("CSR") of the Act are not applicable to the company. Accordingly, reporting under clause 3(XX) of the Order is not applicable for the year.

For **MUKESH M. SHAH & CO.,**
Chartered Accountants
Firm Registration No.: 106625W

SD/-

Suvrat S. Shah
Partner
Membership No.: 102651

Place: Ahmedabad
Date: 29th April, 2026
UDIN: 26102651ZANIKT5880

“ANNEXURE B” TO THE AUDITORS’ REPORT

Report on the Internal Financial Control clause (i) of sub-section 3 of section 143 of the Companies Act, 2013 (“the Act”)

We have audited the internal financial controls over financial reporting of **Liva Nutritions Limited** (“the Company”) as of March 31, 2026 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management Responsibility for Internal Financial Controls

The Company’s management is responsible for establishing and maintaining internal financial control based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India [“ICAI”]. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditors’ Responsibility

Our responsibility is to express an opinion on the Company’s internal financial controls over financial reporting of the Company based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (“the Guidance Note”) issued by the Institute of Chartered Accountants of India and the Standards on Auditing prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial control system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgement, including the assessment of the material misstatement of the Standalone financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A Company’s internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A Company’s internal financial control over financial reporting includes those policies and procedures that:

1. pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;

2. provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and
3. provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2026, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For **MUKESH M. SHAH & CO.,**
Chartered Accountants
Firm Registration No.: 106625W

SD/-

Suvrat S. Shah
Partner
Membership No.: 102651

Place: Ahmedabad
Date: 29th April, 2026
UDIN: 26102651ZANIKT5880

Balance Sheet as at March 31, 2026

Particulars	Note No.	₹ in Thousand	
		As at March 31	
		2026	2025
ASSETS:			
Non-current assets:			
Financial assets:			
Investments	3	23,357	23,357
Total Non-Current Assets		23,357	23,357
Current assets:			
Financial assets:			
Cash and cash equivalents	4	631	668
Total Current Assets		631	668
Total Assets		23,988	24,025
EQUITY AND LIABILITIES:			
EQUITY:			
Equity share capital	5	30,500	30,500
Other equity	6	(6,556)	(6,523)
Total Equity		23,944	23,977
LIABILITIES:			
Current liabilities:			
Financial liabilities:			
Trade payables:			
Dues to Micro and Small Enterprises	7	35	39
Dues to other than Micro and Small Enterprises	7	-	-
Current tax liabilities [net]	8	9	9
Total Current Liabilities		44	48
Total Liabilities		44	48
Total Equity and Liabilities		23,988	24,025
Material Accounting Policies	2		
Notes to the Financial Statements	3 to 22		
As per our report of even date For and on behalf of the Board For Mukesh M. Shah & Co. Chartered Accountants Firm Registration Number: 106625W			
Sd/- Sd/- Sd/- Suvrat Shah Dr. Sharvil P. Patel Tarun Arora Partner Chairman Director Membership Number: 102651 DIN: 00131995 DIN: 07185311 Place: Ahmedabad Place: Ahmedabad Place: Ahmedabad Date: May 16, 2026 Date: May 16, 2026 Date: May 16, 2026			

Liva Nutritions Limited [CIN: U15149GJ2018PLC105736]			
Statement of Profit and Loss for the year ended March 31, 2026			
Particulars	Note No.	₹ in Thousand	
		Year ended March 31	
		2026	2025
INCOME:			
Other income	9	34	35
Total Income		34	35
EXPENSES:			
Finance cost	10	2	1
Other expenses	11	55	51
Total Expenses		57	52
Loss before Tax		(23)	(17)
Less: Tax expense:			
Current tax	12	(10)	(6)
Deferred tax	12	-	-
		(10)	(6)
Loss for the year		(33)	(23)
Other Comprehensive Income for the year [net of tax]		-	-
Total Comprehensive Loss for the year [net of tax]		(33)	(23)
Basic and Diluted Earnings per equity share [EPS] [in ₹]	13	(0.66)	(0.46)
Material Accounting Policies	2		
Notes to the Financial Statements	3 to 22		
As per our report of even date For Mukesh M. Shah & Co. Chartered Accountants Firm Registration Number: 106625W For and on behalf of the Board			
Sd/- Suvrat Shah Partner Membership Number: 102651 Place: Ahmedabad Date: May 16, 2026 Sd/- Dr. Sharvil P. Patel Chairman DIN: 00131995 Place: Ahmedabad Date: May 16, 2026 Sd/- Tarun Arora Director DIN: 07185311 Place: Ahmedabad Date: May 16, 2026			

Liva Nutritions Limited [CIN: U15149GJ2018PLC105736]
Cash Flow Statement for the year ended March 31, 2026

Particulars	₹ in Thousand	
	Year ended March 31	
	2026	2025
A. Cash flows from operating activities:		
Loss before tax	(23)	(17)
Adjustment for:		
Interest expense	2	1
Interest income	(34)	(35)
Operating loss before working capital changes	(55)	(51)
Adjustment for:		
Increase in trade payables	(4)	4
Net cash used in operating activities	(59)	(47)
Direct taxes paid	(10)	3
Net cash used in operating activities	(69)	(44)
B. Cash flows from investing activities:		
Interest income	34	35
Change in Bank balances (including fixed deposits) not considered as cash and cash equivalents	-	3
Net cash from investing activities	34	38
C. Cash flows from financing activities:		
Interest paid	(2)	(1)
Net cash used in financing activities	(2)	(1)
Net decrease in cash and cash equivalents [A+B+C]	(37)	(7)
Cash and cash equivalents at the beginning of the year	668	675
Cash and cash equivalents at the end of the year	631	668

Notes to the Cash Flow Statement

- The above cash flow statement has been prepared under the "Indirect method" as set out in Ind AS-7 "Statement of Cash Flows".
- All figures in brackets are outflows.
- Previous year's figures have been regrouped wherever necessary.
- Cash and cash equivalents comprise of:

₹ in Thousand

Particulars	Note No.	As at March 31		
		2026	2025	2024
a. Cash and cash equivalents	4	631	668	675
Total		631	668	678

As per our report of even date

For and on behalf of the Board

For Mukesh M. Shah & Co.

Chartered Accountants

Firm Registration Number: 106625W

Sd/-

Suvrat Shah

Partner

Membership Number: 102651

Place: Ahmedabad

Date: May 16, 2026

Sd/-

Dr. Sharvil P. Patel

Chariman

DIN: 00131995

Place: Ahmedabad

Date: May 16, 2026

Sd/-

Tarun Arora

Director

DIN: 07185311

Place: Ahmedabad

Date: May 16, 2026

Liva Nutritions Limited [CIN: U15149GJ2018PLC105736]		
Statement of Changes in Equity for the year ended March 31, 2026		
a Equity share capital:		
	No. of Shares	₹ in Thousand
Equity shares of ₹ 10/- each, Issued, subscribed and fully paid-up:		
As at March 31, 2024	50,000	500
As at March 31, 2025	50,000	500
As at March 31, 2026	50,000	500
7% Optionally Convertible Non-Cumulative Redeemable Preference Shares of ₹ 10/- each, Issued, subscribed and fully paid-up:		
As at March 31, 2024	3,000,000	30,000
As at March 31, 2025	3,000,000	30,000
As at March 31, 2026	3,000,000	30,000
b Other equity:		
₹ in Thousand		
Particulars	Retained Earnings	Total
As at March 31, 2024	(6,500)	(6,500)
Add: Loss for the year	(23)	(23)
As at March 31, 2025	(6,523)	(6,523)
Add: Loss for the year	(33)	(33)
As at March 31, 2026	(6,556)	(6,556)
As per our report of even date	For and on behalf of the Board	
For Mukesh M. Shah & Co.		
Chartered Accountants		
Firm Registration Number: 106625W		
Sd/-	Sd/-	Sd/-
Suvrat Shah	Dr. Sharvil P. Patel	Tarun Arora
Partner	Chariman	Director
Membership Number: 102651	DIN: 00131995	DIN: 07185311
Place: Ahmedabad	Place: Ahmedabad	Place: Ahmedabad
Date: May 16, 2026	Date: May 16, 2026	Date: May 16, 2026

Liva Nutritions Limited

Note: 1 - Company overview:

Liva Nutritions Limited ["the Company"] [CIN: U15149GJ2018PLC105736] was incorporated on December 21, 2018 and operates as an integrated consumer Company with business encompassing the entire value chain in the development, production, marketing and distribution of health and wellness products. The registered office of the Company is located at Zydus Corporate Park, Scheme No. 63, Survey No. 536 Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382481. These financial statements were authorised for issuance in accordance with a resolution passed by Board of Directors at its meeting held on May 16, 2026.

Note: 2 - Material Accounting Policies:

- A** The following note provides list of the material accounting policies adopted in the preparation of these financial statements. These policies have been consistently applied to all the years presented unless otherwise stated.
- 1 Basis of preparation:**
 - A** The Standalone financial statements have been prepared in all material aspects in accordance with the Indian Accounting Standards [Ind AS] notified under section 133 of the Companies Act, 2013 read with [Indian Accounting Standards] Rules, 2015, as amended and other relevant provisions of the Companies Act, 2013.
 - B** The financial statements have been prepared on historical cost basis, except for certain financial assets and liabilities [refer accounting policy regarding financial instruments] which have been measured at fair value at the end of the reporting periods.
 - 2 Use of key Estimates and Judgments:**

The preparation of the financial statements in conformity with Ind AS requires management to make estimates, judgments and assumptions. These estimates, judgments and assumptions affect the application of accounting policies and the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of income and expenses during the period. Application of accounting policies that require critical accounting estimates involving complex and subjective judgments are provided below. Accounting estimates could change from period to period. Actual results could differ from those estimates. Appropriate changes in estimates are made as management becomes aware of changes in circumstances surrounding the estimates. Changes in estimates are reflected in the financial statements in the period in which changes are made and, if material, their effects are disclosed in the notes to the financial statements.

Critical accounting judgments and estimates:

 - A Taxes on Income:**

Significant judgments are involved in determining the provision for income taxes, including amount expected to be paid/recovered for uncertain tax positions and possibility of utilisation of Minimum Alternate Tax [MAT] credit in future. [Refer Note 2 (4)]
 - B Impairment of investments:**

Significant judgments are involved in determining the estimated future cash flows from the Investments to determine their value in use to assess whether there is any impairment in their carrying amounts as reflected in the financials. [Refer Note 2 (9)]
 - 3 Revenue Recognition:**
 - A** The specific recognition criteria described below must also be met before revenue is recognised:
 - a Interest Income:**

For all debt instruments measured at amortised cost, interest income is recorded using the effective interest rate [EIR]. EIR is the rate that discounts the estimated future cash payments or receipts over the expected life of the financial instrument or a shorter period, where appropriate, to the gross carrying amount of the financial asset or to the amortised cost of a financial liability. When calculating the effective interest rate, the Company estimates the expected cash flows by considering all the contractual terms of the financial instrument but does not consider the expected credit losses.
 - 4 Taxes on Income:**

Tax expenses comprise of current and deferred tax.

 - A Current Tax:**
 - a** Current tax is measured at the amount expected to be paid on the basis of reliefs and deductions available in accordance with the provisions of the Income Tax Act, 1961. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date.
 - b** Current tax items are recognised in correlation to the underlying transaction either in profit or loss, Other Comprehensive Income (OCI) or directly in equity.
 - B Deferred Tax:**
 - a** Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.
 - b** Deferred tax liabilities are recognised for all taxable temporary differences.
 - c** Deferred tax assets are recognised for all deductible temporary differences including the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, the carry forward of unused tax credits and unused tax losses can be utilized.
 - d** The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Unrecognised deferred tax assets are re-assessed at each reporting date and are recognised to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.
 - e** Deferred tax assets and liabilities are measured at the tax rates [and tax laws] that have been enacted or substantively enacted at the reporting date and are expected to apply in the year when the asset is realised or the liability is settled.
 - f** Deferred tax items are recognised in correlation to the underlying transaction either in profit or loss, OCI or directly in equity.
 - g** Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current tax liabilities.
 - 5 Borrowing Costs:**
 - A** Borrowing costs consist of interest and other borrowing costs that are incurred in connection with the borrowing of funds. Other borrowing costs include ancillary charges at the time of acquisition of a financial liability, which is recognised as per EIR method.
 - 6 Cash and Cash Equivalents:**

Cash and Cash Equivalents for the purpose of Cash Flow Statement comprise cash and cheques in hand, bank balances and demand deposits with banks.
 - 7 Provisions, Contingent Liabilities and Contingent Assets:**
 - A** Provisions are recognised when the Company has a present obligation as a result of past events and it is probable that the outflow of resources will be required to settle the obligation and in respect of which reliable estimates can be made. A disclosure for contingent liability is made when there is a possible obligation, that may, but probably will not require an outflow of resources. When there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision/ disclosure is made. Provisions and contingencies are reviewed at each balance sheet date and adjusted to reflect the correct management estimates. Contingent assets are not recognised but are disclosed separately in financial statements.
 - B** If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, when appropriate, the risks specific to the liability.

8 Dividends :

The final dividend on shares is recorded as a liability on the date of approval by the shareholders and interim dividend is recorded as liability on the date of declaration by the Company's Board of Directors.

9 Financial Instruments:

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

A Financial assets:

a Initial recognition and measurement:

All financial assets are recognised initially at fair value plus, in the case of financial assets not recorded at fair value through profit or loss, transaction costs that are attributable to the acquisition of the financial asset. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place [regular way trades] are recognised on the settlement date, i.e., the date that the Company settle to purchase or sell the asset. However, trade receivables that do not contain a significant financing component are measured at transaction price.

b Subsequent measurement:

For purposes of subsequent measurement, financial assets are classified in five categories:

i Debt instruments at amortised cost:

A 'debt instrument' is measured at the amortised cost if both the following conditions are met:

- The asset is held with an objective of collecting contractual cash flows
- Contractual terms of the asset give rise on specified dates to cash flows that are "solely payments of principal and interest" [SPPI] on the principal

After initial measurement, such financial assets are subsequently measured at amortised cost using the effective interest rate [EIR] method. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included in finance income in the Statement of Profit and Loss. The losses arising from impairment are recognised in the Statement of profit and loss.

ii Debt instruments at fair value through other comprehensive income [FVTOCI]:

A 'debt instrument' is classified as at the FVTOCI if both of the following criteria are met:

- The asset is held with objectives of both collecting contractual cash flows and selling the financial assets
- The asset's contractual cash flows represent SPPI.

Debt instruments included within the FVTOCI category are measured initially as well as at each reporting date at fair value. Fair value movements are recognized in the OCI. However, the Company recognizes interest income, impairment losses & reversals and foreign exchange gain or loss in the Statement of Profit and Loss. On derecognition of the asset, cumulative gain or loss previously recognised in OCI is reclassified from the equity to Statement of Profit and Loss. Interest earned whilst holding FVTOCI debt instrument is reported as interest income using the EIR method.

iii Debt instruments and derivatives at fair value through profit or loss [FVTPL]:

FVTPL is a residual category for debt instruments. Any debt instrument, which does not meet the criteria for categorization as at amortized cost or as FVTOCI, is classified as at FVTPL. Instruments included within the FVTPL category are measured at fair value with all changes recognized in the Statement of Profit and Loss.

iv Equity instruments:

All equity investments in scope of Ind AS 109 are measured at fair value. Equity instruments which are held for trading are classified as at FVTPL. For all other equity instruments, the Company may make an irrevocable election to present subsequent changes in the fair value in other comprehensive income . The Company has made such election on an instrument by instrument basis. The classification is made on initial recognition and is irrevocable.

If the Company decides to classify an equity instrument as at FVTOCI, then all fair value changes on the instrument, excluding dividends, are recognized in the OCI. There is no recycling of the amounts from OCI to Statement of Profit and Loss, even on sale of investment.

However, the Company may transfer the cumulative gain or loss within equity.

Equity instruments included within the FVTPL category are measured at fair value with all changes recognized in the Statement of Profit and Loss.

v Investments in subsidiaries :

Investments in subsidiaries are carried at cost less accumulated impairment losses, if any. Where an indication of impairment exists, the carrying amount of the investment is assessed and written down immediately to its recoverable amount. On disposal of investments in subsidiaries, the differences between net disposal proceeds and the carrying amounts are recognised in the statement of profit and loss.

c Derecognition:

A financial asset [or, where applicable, a part of a financial asset] is primarily derecognised [i.e., removed from Company's balance sheet] when:

- The rights to receive cash flows from the asset have expired, or
- The Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement; and either [a] the Company has transferred substantially all the risks and rewards of the asset, or [b] the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Company has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Company continues to recognise the transferred asset to the extent of the Company's continuing involvement. In that case, the Company also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Company has retained. When the Company has transferred the risk and rewards of ownership of the financial asset, the same is derecognised.

d Impairment of financial assets:

In accordance with Ind AS 109, the Company applies expected credit loss [ECL] model for measurement and recognition of impairment loss on trade receivables or any contractual right to receive cash or another financial asset.

The Company follows 'simplified approach' for recognition of impairment loss allowance for trade receivables or any contractual right to receive cash or another financial asset. The application of simplified approach does not require the Company to track changes in credit risk. Rather, it requires the Company to recognise the impairment loss allowance based on lifetime ECLs at each reporting date, right from its initial recognition.

For recognition of impairment loss on other financial assets and risk exposure, the Company determines that whether there has been a significant increase in the credit risk since initial recognition. If credit risk has not increased significantly, 12-month ECL is used to provide for impairment loss. However, if credit risk has increased significantly, lifetime ECL is used. If, in a subsequent period, credit quality of the instrument improves such that there is no longer a significant increase in credit risk since initial recognition, then the entity reverts to recognising impairment loss allowance based on 12-month ECL. Lifetime ECL are the expected credit losses resulting from all possible default events over the expected life of a financial instrument. The 12-month ECL is a portion of the lifetime ECL which results from default events that are possible within 12 months after the reporting date. ECL is the difference between all contractual cash flows that are due to the Company in accordance with the contract and all the cash flows that the entity expects to receive [i.e., all cash shortfalls], discounted at the original EIR.

ECL impairment loss allowance [or reversal] is recognized as expense/ income in the Statement of profit and loss. The balance sheet presentation for various financial instruments is described below:

Financial assets measured as at amortised cost and contractual revenue receivables: ECL is presented as an allowance , i.e., as an integral part of the measurement of those assets in the balance sheet, which reduces the net carrying amount. Until the asset meets write-off criteria, the Group does not reduce impairment allowance from the gross carrying amount.

For assessing increase in credit risk and impairment loss, the Group combines financial instruments on the basis of shared credit risk characteristics.

B Financial liabilities:**a Initial recognition and measurement:**

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, payables, or as derivatives designated as hedging instruments in an effective hedge, as appropriate. All financial liabilities are recognised initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

b Subsequent measurement:

Subsequently all financial liabilities are measured at amortised cost, using EIR method. Gains and losses are recognised in Statement of profit and loss when the liabilities are derecognised as well as through the EIR amortisation process. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included as finance costs in the Statement of profit and loss.

c Derecognition:

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the statement of profit and loss.

d Embedded derivatives:

An embedded derivative is a component of a hybrid [combined] instrument that also includes a non-derivative host contract – with the effect that some of the cash flows of the combined instrument vary in a way similar to a standalone derivative. Derivatives embedded in all other host contracts are accounted for as separate derivatives and recorded at fair value if their economic characteristics and risks are not closely related to those of the host contracts and the host contracts are not held for trading or designated at fair value through profit or loss. These embedded derivatives are measured at fair value with changes in fair value recognised in statement of profit or loss, unless designated as effective hedging instruments.

C Reclassification of financial assets:

The Company determines classification of financial assets and liabilities on initial recognition. After initial recognition, no reclassification is made for financial assets which are equity instruments and financial liabilities. For financial assets which are debt instruments, a reclassification is made only if there is a change in the business model for managing those assets. Changes to the business model are expected to be infrequent. The Company's senior management determines change in the business model as a result of external or internal changes which are significant to the Company's operations. Such changes are evident to external parties. A change in the business model occurs when the Company either begins or ceases to perform an activity that is significant to its operations. If the Company reclassifies financial assets, it applies the reclassification prospectively from the reclassification date which is the first day of the immediately next reporting period following the change in business model as per Ind AS 109.

D Offsetting of financial instruments:

Financial assets and financial liabilities are offset and the net amount is reported in the balance sheet if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously.

10 Fair Value Measurement:

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- a In the principal market for the asset or liability, or
- b In the absence of a principal market, in the most advantageous market for the asset or liability

The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest. A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use. The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- a Level 1 — Quoted [unadjusted] market prices in active markets for identical assets or liabilities
- b Level 2 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable
- c Level 3 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable

For assets and liabilities that are recognised in the financial statements on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by re-assessing categorisation [based on the lowest level input that is significant to the fair value measurement as a whole] at the end of each reporting period.

11 Earnings per Share:

Basic earnings per share is calculated by dividing the net profit or loss [excluding other comprehensive income] for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the year. The weighted average number of equity shares outstanding during the year is adjusted for events such as bonus issue, bonus element in a right issue, shares split and reserve share splits [consolidation of shares] that have changed the number of equity shares outstanding, without a corresponding change in resources.

For the purpose of calculating diluted earnings per share, the net profit or loss [excluding other comprehensive income] for the year attributable to equity shareholders and the weighted average number of shares outstanding during the year are adjusted for the effects of all dilutive potential equity shares.

B Recent Accounting Pronouncements:

The Ministry of Corporate Affairs [MCA] notifies new standards or amendments to existing standards under the Companies [Indian Accounting Standards] Rules from time to time. MCA has notified amendments to Ind AS 1 – Presentation of Financial Statements [classification of liabilities as Current or Non-current, including liabilities with covenants], Ind AS 12 – Income Taxes [International Tax Reform – Pillar Two Model Rules], Ind AS 21 – The Effects of Changes in Foreign Exchange Rates [Lack of Exchangeability] and Ind AS 7 – Statement of Cash Flows and Ind AS 107 – Financial Instruments: Disclosures [Supplier Finance Arrangements], effective from April 1, 2025. The Company has reviewed these amendments and based on its evaluation, has determined that they do not have any material impact on the Company's financial statements.

New standards or amendments not yet adopted:

Classification of Liabilities as Current or Non-current and Non-current Liabilities with Covenants – Amendments to Ind AS 1. The amendments clarify that lender waivers obtained after the reporting date cannot be considered for the purpose of classifying liabilities as current or non current and require retrospective application in accordance with Ind AS 8. These amendments are effective for reporting periods beginning on or after April 1, 2026. The Company does not expect any material impact on its financial statements.

Liva Nutritions Limited
Notes to the Financials Statements

Note: 3 - Investments [Non-Current]:

		₹ in Thousand	
	Face Value [*]	Nos. [**]	As at March 31
			2026 2025
Investments in fellow subsidiaries			
Investments in equity instruments			23,357 23,357
Total			23,357 23,357
A Details of investments in fellow subsidiaries			
Investments in equity instruments [valued at cost]:			
In fully paid-up equity shares of:			
Zydus Wellness Products Limited	10	2,329,933	23,357 23,357
Zydus Wellness (BD) Pvt Limited [₹ 88]	BDT 10	9	0 0
Total			23,357 23,357
B Aggregate book value of unquoted investment			23,357 23,357
C Explanations:			
a. In "Face Value [*]", figures in Indian ₹, unless stated otherwise.			
b. In "Nos. [**]" figures of previous year are same unless stated in [].			

Note: 4 - Cash and cash equivalents:

		₹ in Thousand	
		As at March 31	
		2026 2025	
Balances with banks		631 668	
Total		631 668	

Note: 5 - Equity share capital:

		₹ in Thousand	
		As at March 31	
		2026 2025	
Authorised:			
1,00,000 [as at March 31, 2025: 1,00,000] Equity shares of ₹ 10 each	₹ in Thousand	1,000	1,000
30,00,000 [as at March 31, 2025: 30,00,000] 7% Optionally Convertible Non-Cumulative Redeemable Preference shares of ₹ 10 each	₹ in Thousand	30,000	30,000
		31,000	31,000
Issued, subscribed and fully paid-up:			
50,000 [as at March 31, 2025: 50,000] Equity shares of ₹ 10 each	₹ in Thousand	500	500
30,00,000 [as at March 31, 2025: 30,00,000] 7% Optionally Convertible Non-Cumulative Redeemable Preference shares of ₹ 10 each	₹ in Thousand	30,000	30,000
Total		30,500	30,500
A. The reconciliation in number of Equity shares is as under:			
Number of shares at the beginning and end of the year		50,000	50,000
B. The reconciliation in number of 7% Optionally Convertible Non-Cumulative Redeemable preference shares is as under:			
Number of shares at the beginning and end of the year		30,00,000	30,00,000
C. The Company has issued equity shares and preference shares. All equity shares rank pari passu and carry equal rights with respect to voting and dividend. In the event of liquidation of the Company, the equity shareholders shall be entitled to proportionate share of their holding in the assets remained after distribution of all preferential amounts.			
D. 7% Optionally Convertible Non-Cumulative Redeemable Preference shares [OCRPS] are redeemable at par. At anytime during the tenure of the OCRPS, the Issuer of the OCRPS shall have right to have all, or any part, of the OCRPS to be converted as Equity Shares. At anytime during the tenure of the OCRPS, the Holder of the OCRPS shall have right to have all, or any part, of the OCRPS to be converted as Equity Shares. Such conversation shall happen at a pre-determined agreed rate between the parties. The tenure of the OCRPS shall be 10 years from the date of allotment. At any time during the tenure of the OCRPS, the Company shall have a right to redeem, all or any part of outstanding OCRPS. The OCRPS shall carry a preferential right with respect to dividend on the paid up capital in the event of distribution of profits by the company.			
E. Details of Shareholder holding more than 5% of total equity of the Company			
a. Equity shares:			
Zydus Wellness Limited and its nominees			
Number of Shares		50,000	50,000
% to total share holding		100.00%	100.00%
b. Preference shares:			
Zydus Wellness Limited			
Number of Shares		30,00,000	30,00,000
% to total share holding		100.00%	100.00%
F. Number of shares held by Holding Company and its nominees			
a. Equity shares:			
Zydus Wellness Limited		50,000	50,000
b. Preference shares:			
Zydus Wellness Limited		30,00,000	30,00,000

Liva Nutritions Limited
Notes to the Financials Statements

G. Details of Equity Shares held by promoters/ promoter group.

Sr. No.	Promoter's/ Promoter Group's Name	As at March 31, 2026			As at March 31, 2025		
		No. of Shares	% of total shares	% change during the year	No. of Shares	% of total shares	% change during the year
1	Zydus Wellness Limited	50,000	100.00%	0.00%	50,000	100.00%	0.00%

H. Details of Preference Shares held by promoters/ promoter group.

Sr. No.	Promoter's/ Promoter Group's Name	As at March 31, 2026			As at March 31, 2025		
		No. of Shares	% of total shares	% change during the year	No. of Shares	% of total shares	% change during the year
1	Zydus Wellness Limited	3,000,000	100.00%	0.00%	3,000,000	100.00%	0.00%

Note: 6 - Other equity:

		₹ in Thousand	
		As at March 31	
		2026	2025
Retained Earnings:			
Balance as per last Balance Sheet		(6,523)	(6,500)
Add: Loss for the year		(33)	(23)
Balance as at the end of the year		(6,556)	(6,523)
Total		(6,556)	(6,523)

Note: 7 - Trade payables:

		₹ in Thousand	
		As at March 31	
		2026	2025
Dues to Micro and Small Enterprises [*]		35	39
Dues to other than Micro and Small Enterprises		-	-
Total		35	39
[*] Disclosure in respect of Micro and Small Enterprises:			
A. Principal amount remaining unpaid to any supplier as at year end		35	39
B. Interest due thereon		-	-
C. Amount of interest paid by the Company in terms of section 16 of the MSMED Act, along with the amount of the payment made to the supplier beyond the appointed day during the year.		-	-
D. Amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the MSMED Act.		-	-
E. Amount of interest accrued and remaining unpaid at the end of the accounting year.		-	-
F. Amount of further interest remaining due and payable in succeeding years.		-	-
The above information has been compiled in respect of parties to the extent to which they could be identified as Micro and Small Enterprises on the basis of information available with the Company.			

Ageing of Trade payables :

[A] As at March 31, 2026

		₹ in Thousand				
Particulars	Not Due	Outstanding for following periods from due date of payment				Total
		Less than 1 year	1 to 2 years	2 to 3 years	More than 3 years	
Undisputed Micro and Small Enterprises [MSME]	35	-	-	-	-	35
Undisputed Others	-	-	-	-	-	-
Disputed MSME	-	-	-	-	-	-
Disputed Others	-	-	-	-	-	-
Total	35	-	-	-	-	35

[B] As at March 31, 2025

		₹ in Thousand				
Particulars	Not Due	Outstanding for following periods from due date of payment				Total
		Less than 1 year	1 to 2 years	2 to 3 years	More than 3 years	
Undisputed Micro and Small Enterprises [MSME]	39	-	-	-	-	39
Undisputed Others	-	-	-	-	-	-
Disputed MSME	-	-	-	-	-	-
Disputed Others	-	-	-	-	-	-
Total	39	-	-	-	-	39

Liva Nutritions Limited
Notes to the Financials Statements

Note: 8 - Current tax liabilities [net]:

		₹ in Thousand
		As at March 31
	2026	2025
Provision for taxation	9	9
Total	9	9

Note: 9 - Other income:

		₹ in Thousand
		Year ended March 31
	2026	2025
Finance income:		
Interest income on financial assets measured at amortised cost	34	35
Total	34	35

Note: 10 - Finance Cost:

		₹ in Thousand
		Year ended March 31
	2026	2025
Interest expense [*]	2	-
Other finance cost [₹ 234]	-	1
Total	2	1
[*] Interest expenses includes:		
On others	2	-
Total	2	-

Note: 11 - Other expenses:

		₹ in Thousand
		Year ended March 31
	2026	2025
Legal and professional fees [*]	45	51
Rates and Taxes	10	-
Total	55	51
[*] Legal and professional fees include:		
a Payment to the Statutory Auditors [excluding Taxes]:		
As an Auditor	30	30
Total	30	30
Notes:		
1 No amount is required to be spent during the year on Corporate Social Responsibility [CSR] Activities as required u/s 135 of the Companies Act, 2013	-	-

Note: 12 - Tax Expenses:

		₹ in Thousand
		Year ended March 31
	2026	2025
The major components of income tax expense are:		
A. Statement of profit and loss:		
Profit or loss section:		
Current income tax:		
Current income tax charge	9	9
Adjustments in respect of current income tax of previous year	1	(3)
	10	6
Deferred tax:		
Deferred tax relating to origination and reversal of temporary differences [*]	-	-
Total reported in profit or loss	10	6
OCI Section:		
Tax related to items recognised in OCI during in the year	-	-
Tax charged to OCI	-	-

[*] Considering principle of prudence, deferred tax assets are not recognized in absence of convincing evidence that sufficient taxable income will be available against which such deferred tax assets can be realised.

Liva Nutritions Limited Notes to the Financial Statements			
Note: 13 - Calculation of Earnings per equity share [EPS]:			
		Year ended March 31	
		2026	2025
The numerators and denominators used to calculate the basic and diluted EPS are as follows:			
A	Loss attributable to Shareholders	₹- in Thousand (33)	(23)
B	Basic and weighted average number of Equity shares outstanding during the year	Numbers 50,000	50,000
C	Effect of dilution - 7% Optionally Convertible Non-cumulative Redeemable Preference Shares [*]	Numbers 3,000,000	3,000,000
D	Nominal value of equity share	₹ 10	10
E	Basic and Diluted EPS [*]	₹ (0.66)	(0.46)
[*] Antidilutive effect of conversion of preference shares into potential equity shares is ignored in calculation of dilutive EPS.			
Note: 14 - Segment Information:			
Segment Information has been given in the Consolidated Financial Statements of the Holding Company. Hence, as per Ind AS-108 "Operating Segments" issued by the Ministry of Corporate Affairs, no separate disclosure on segment information is given in these financial statements.			
Note: 15 - Related Party Transactions:			
A Name of the Related Parties and Nature of the Related Party Relationship with whom transactions have taken place:			
a Ultimate Holding Company: Zydus Lifesciences Limited			
b Holding Company: Zydus Wellness Limited			
c Fellow Subsidiaries/ Concerns:			
Zydus Wellness Products Limited	Zydus Lifesciences Global FZE [UAE]		
Liva Investment Limited [upto August 20, 2025]	Zydus Healthcare (USA) LLC [USA]		
Zydus Wellness (BD) Pvt Limited [Bangladesh]	Sentynl Therapeutics Inc. [USA]		
Zydus Healthcare Limited	Viona Pharmaceuticals Inc. [USA]		
German Remedies Pharmaceuticals Private Limited	Zydus Therapeutics Inc. [ZTI] [USA]		
Zydus Animal Health and Investments Limited	Zydus Healthcare S.A. (Pty) Ltd [South Africa]		
Dialforhealth Unity Limited	Alidac Pharmaceuticals SA Pty. Ltd. [South Africa]		
Dialforhealth Greencross Limited	Script Management Services (Pty) Ltd [South Africa]		
Violio Healthcare Limited	Zydus France, SAS [France]		
Zydus Pharmaceuticals Limited	Laboratorios Comib S.L. [Spain]		
Biochem Pharmaceutical Private Limited	Etna Biotech S.R.L. [Italy] [Under Liquidation]		
Zydus Strategic Investments Limited	Zydus Nikkho Farmaceutica Ltda. [Brazil]		
Zydus VTEC Limited	Zydus Pharmaceuticals Mexico SA De CV [Mexico]		
Zydus Medtech Private Limited	Zydus Pharmaceuticals Mexico Services Company SA De C.V. [Mexico]		
Naturell (India) Private Limited [*]	Nesher Pharmaceuticals (USA) LLC [USA]		
Naturell Inc. [USA]	[merged with Zydus Pharmaceuticals (USA) Inc. [USA] on October 25, 2024]		
Zydus Wellness International DMCC [UAE]	Zydus Pharmaceuticals UK Ltd. [UK]		
M/s Recon Pharmaceuticals and Investments, a Partnership Firm	Zynext Ventures Pte. Ltd. [Singapore]		
LM Manufacturing India Private Limited	LM Manufacturing Limited [UK]		
Alidac Healthcare (Myanmar) Limited [Myanmar]	Medsolutions (Europe) Limited [UK]		
Zydus Healthcare Philippines Inc. [Philippines]	Zydus Pharmaceuticals (Canada) Inc. [Canada]		
Zydus Lanka (Private) Limited [Sri Lanka]	Zydus Worldwide DMCC [UAE]		
Zydus International Private Limited [Ireland]	Amplitude Ile de France [France] [w.e.f. July 29, 2025]		
Zydus Netherlands B.V. [the Netherlands]	Duotech Amplitude SAS [France] [w.e.f. July 29, 2025]		
Zydus Pharmaceuticals (USA) Inc. [USA]	Amplitude Sud SAS [France] [w.e.f. July 29, 2025]		
ZyVet Animal Health Inc. [USA]	Amplitude Nord SAS [France] [w.e.f. July 29, 2025]		
Zynext Ventures USA LLC [USA]	Ortho Santé (Amplitude Ouest) [France] [w.e.f. July 29, 2025]		
LiqMeds Worldwide Limited [UK]	Amplitude Benelux [Belgium] [w.e.f. July 29, 2025]		
LiqMeds Limited [UK]	Amplitude Suisse SA [Switzerland] [w.e.f. July 29, 2025]		
LiqMeds Lifecare Limited [UK] [LiqMed]	Amplitude GmbH [Germany] [w.e.f. July 29, 2025]		
Zylidac Bio LLC [USA] [w.e.f. July 11, 2025]	Amplitude New Zealand Limited [New Zealand] [w.e.f. July 29, 2025]		
Zydus MedTech (France) SAS [France] [w.e.f. April 10, 2025]	Auroralux [Luxemburg] [w.e.f. July 29, 2025 till December 31,2025]		
Amplitude Surgical SAS [France] [w.e.f. July 29, 2025]	Ampliman 1 [France] [w.e.f. July 29, 2025 till January 16,2026]		
Amplitude Orthopedics Corporation [USA] [w.e.f. July 29, 2025]	Ampliman 2 [France] [w.e.f. July 29, 2025 till January 9,2026]		
Amplitude Australia Pty Ltd [Australia] [w.e.f. July 29, 2025]	Alidac UK Limited [w.e.f. August 5, 2025]		
Amplitude South Africa Pty Ltd [South Africa] [w.e.f. July 29, 2025]	Comfort Click Limited [UK] [w.e.f August 29,2025]		
Amplitude Latin America SA [Brazil] [w.e.f. July 29, 2025]	Comfort Click Limited [Ireland] [w.e.f August 29,2025]		
Amplitude SAS [France] [w.e.f. July 29, 2025]	Comfort Click LLC [USA] [w.e.f August 29,2025]		
SCI Les Tilleuls [France] [w.e.f. July 29, 2025]	Comfort Click Softech Pvt. Ltd. [w.e.f August 29,2025]		
SCI SOFAB FALLA [France] [w.e.f. July 29, 2025]	Mediconseil [w.e.f. December 19, 2025]		
d Joint Venture [JV] companies of Ultimate Holding Company and Fellow Subsidiary Companies:			
Zydus Hospira Oncology Private Limited	Bayer Zydus Pharma Private Limited [Upto May 2, 2024]		
Zydus Takeda Healthcare Private Limited	Oncosol Limited [JV of LiqMed]		
Sterling Biotech Limited [w.e.f. August 29, 2024] [JV of ZAHIL]			
e Directors:			
Dr. Sharvil P. Patel	Chairman		
Mr. Tarun Arora	Director		
Ms. Bhavna S. Doshi	Director [upto March 06, 2025]		
Mr. Umesh V. Parikh	Director [W.e.f. March 28, 2025]		

Liva Nutritions Limited
Notes to the Financials Statements

B Transactions with Related Parties:

There are no transactions with related parties mentioned in Note - 15 [A].

[*] Pursuant to voluntary liquidation, the business undertaking was distributed to Zydus Wellness Limited w.e.f. September 20, 2025 and the application for dissolution is under process with Hon'ble National Company Law Tribunal, Ahmedabad Bench.

Note: 16 - Financial instruments:

(i) Fair values hierarchy:

Financial assets and financial liabilities measured at fair value in the statement of financial position are grouped into three Levels of a fair value hierarchy. The three Levels are defined based on the observability of significant inputs to the measurement, as follows:

Level 1: Quoted prices (unadjusted) in active markets for financial instruments.

Level 2: The fair value of financial instruments that are not traded in an active market is determined using valuation techniques which maximise the use of observable market data relying as little as possible on entity specific estimates.

Level 3: If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3.

(ii) Fair value of instruments measured at amortised cost:

Financial assets and liabilities measured at amortised cost for which fair values are disclosed.

Financial Assets: The carrying amounts of cash and cash equivalents are considered to be the approximately equal to the fair values.

Financial Liabilities: The carrying amounts of trade payables are considered to be approximately equal to the fair values.

Note: 17 - Financial risk management:

(i) Financial instruments by category:

₹ in Thousand

Particulars	As at March 31, 2026				As at March 31, 2025			
	FVTPL	FVOCI	Amortised Cost	Total	FVTPL	FVOCI	Amortised Cost	Total
Financial assets								
Cash and cash equivalents	-	-	631	631	-	-	668	668
Total	-	-	631	631	-	-	668	668
Financial liabilities								
Trade payables	-	-	35	35	-	-	39	39
Total	-	-	35	35	-	-	39	39

(ii) Risk Management:

The Company's activities expose it to market risk, liquidity risk and credit risk. This note explains the sources of risk which the entity is exposed to and how the entity manages the risk and the related impact in the financial statements.

The Company's risk management is managed in close co-ordination with the board of directors and focuses on actively securing the Company's short, medium and long-term cash flows by minimizing the exposure to volatile financial markets. Long-term financial investments are managed to generate lasting returns.

The Company does not actively engage in the trading of financial assets for speculative purposes nor does it write options. The most significant financial risks to which the Company is exposed are described below:

A. Credit risk:

Credit risk arises from the possibility that counter party may not be able to settle their obligations as agreed. The Company's is exposed to credit risk from bank deposits and other financial assets. The Company periodically assesses the financial reliability of the counter party taking into account the financial condition, current economic trends, analysis of historical bad debts and ageing of accounts receivable. Individual customer limits are set accordingly.

a Investments at amortised Cost : They are strategic investments in the normal course of business of the company.

B Liquidity risk:

a Prudent liquidity risk management implies maintaining sufficient cash and marketable securities and the availability of funding through an adequate amount of committed credit facilities to meet obligations when due. Due to the nature of the business, the Company maintains flexibility in funding by maintaining availability under committed facilities.

b Management monitors rolling forecasts of the Company liquidity position and cash and cash equivalents on the basis of expected cash flows. The Company's account the liquidity of the market in which the entity operates. In addition, the Company liquidity management policy involves projecting cash flows in major currencies and considering the level of liquid assets necessary to meet these, monitoring balance sheet liquidity ratios against internal and external regulatory requirements and maintaining debt financing plans.

Maturities of financial liabilities :

The tables below analyse the Company financial liabilities into relevant maturity Companying's based on their contractual maturities for all non-derivative financial liabilities. The amounts disclosed in the table are the contractual undiscounted cash flows. Balances due within 12 months equal their carrying balances as the impact of discounting is not significant.

₹ in Thousand

Particulars	As at March 31, 2026				
	< 1 year	1-2 years	2-3 years	> 3 years	Total
Non-derivatives financial liabilities					
Trade payables	35	-	-	-	35
Total	35	-	-	-	35

₹ in Thousand

Particulars	As at March 31, 2025				
	< 1 year	1-2 years	2-3 years	> 3 years	Total
Non-derivatives financial liabilities					
Trade payables	39	-	-	-	39
Total	39	-	-	-	39

Liva Nutritions Limited
Notes to the Financials Statements

Note: 18-Analytical Ratios:

Sr.No.	Ratio	Numerator	Denominator	FY 2025-2026	FY 2024-2025	% of variance	Refer note
1	Current Ratio (in times)	Current Assets	Current Liabilities	14.34	13.92	3%	-
2	Debt-Equity Ratio (in times)	Total Debt	Equity	-	-	-	-
3	Debt Service Coverage Ratio (in times)	Earnings available for debt service	Debt Service	-	-	-	-
4	Return on Equity Ratio (in %)	Net Profits after taxes	Average shareholder equity	(0.14)	(0.10)	40%	i
5	Inventory turnover ratio (in times)	Net Sales	Average Inventory	-	-	-	-
6	Trade Receivables turnover ratio (in times)	Net Sales	Average Trade Receivables	-	-	-	-
7	Trade payables turnover	Net Purchases	Average Trade Payables	67.27	72.55	(7%)	-
8	Net capital turnover ratio (in times)	Net Sales	Working Capital	-	-	-	-
9	Net profit ratio (in %)	Net Profits	Net Sales	-	-	-	-
10	Return on Capital employed (in %)	Earnings before interest and taxes	Average Capital Employed	(0.09)	(0.07)	29%	i
11	Return on investments (in %)						
a	Fixed Deposits	Income generated from investments	Average of investments	5.23	5.38	(3%)	-

Notes

- i Due to increase in loss.

Note: 19:

- [a] The Company has not advanced or loaned or invested funds [either from borrowed funds or share premium or any other sources or kind of funds] to any other persons or entities, including foreign entities [Intermediaries], with the understanding, whether recorded in writing or otherwise, that the Intermediary shall directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company [Ultimate Beneficiaries] or provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.
- [b] The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

Note: 20 - Other Statutory Information:

- [a] The Company has not advanced or loaned or invested funds [either from borrowed funds or share premium or any other sources or kind of funds] to any other persons or entities, including foreign entities [Intermediaries], with the understanding, whether recorded in writing or otherwise, that the Intermediary shall directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company [Ultimate Beneficiaries] or provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.
- [b] The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- [c] The Company has used accounting software for maintaining its books of account for the financial year ended March 31, 2026 which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software. The audit trail has been preserved by the company as per the statutory requirements for record retention.
- [d] The Company has not traded or invested in Crypto currency or Virtual currency during the financial year.
- [e] No proceedings have been initiated or pending against the Company for holding any benami property under the Benami Transactions [Prohibition] Act, 1988 (45 of 1988) and the rules made thereunder.
- [f] The Company has not been declared as willful defaulter by any bank or financial institution or other lender.
- [g] The Company does not have any charges or satisfaction yet to be registered with Registrar of Companies beyond the statutory period.
- [h] The Company has complied with the number of layers prescribed under clause [87] of section 2 of the Act read with Companies [Restriction on number of Layers] Rules, 2017.
- [i] No Scheme of Arrangements has been approved by the Competent Authority in terms of sections 230 to 237 of the Companies Act, 2013.
- [j] The Company does not have any transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 [such as, search or survey or any other relevant provisions of the Income Tax Act, 1961].

Liva Nutritions Limited
Notes to the Financial Statements

Note: 21 - Disclosure of Transaction with Struck Off Companies:

The Company did not have any material transaction with companies struck off under Section 248 of the Companies Act, 2013 or Section 560 of Companies Act, 1956 during the current and previous financial year.

Note: 22:

Figures of previous reporting periods have been regrouped/ reclassified wherever necessary to correspond with the figures of the current reporting period.

Signatures to Material Accounting Policies and Notes 1 to 22 to the Financial Statements

As per our report of even date

For Mukesh M. Shah & Co.

Chartered Accountants

Firm Registration Number: 106625W

For and on behalf of the Board

Sd/-

Suvrat Shah

Partner

Membership Number: 102651

Place: Ahmedabad

Date: May 16, 2026

Sd/-

Dr. Sharvil P. Patel

Chairman

DIN: 00131995

Place: Ahmedabad

Date: May 16, 2026

Sd/-

Tarun Arora

Director

DIN: 07185311

Place: Ahmedabad

Date: May 16, 2026